nach oben

Critical Care

Erschienen in:

01.12.2005 | Commentary

Antithrombin in sepsis revisited

verfasst von: Marcel Levi

Erschienen in: Critical Care | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

As the pivotal phase III randomized controlled clinical trial on antithrombin concentrate in patients with severe sepsis did not show a beneficial effect of antithrombin treatment on 28-day mortality, the interest in the potential use of this treatment modality in sepsis has diminished. However, recent data on the effect of antithrombin administration on coagulation in combination with recent analyses from the clinical trials that were aimed to restore physiological anticoagulant pathways in patients with sepsis may revitalize the interest in antithrombin concentrate for the treatment of severe sepsis.

Kountchev J, Bijuklic K, Bellmann R, Wiedermann CJ, Joannidis M: Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 2005, 9: R596-R600. 10.1186/cc3808PubMedCentralCrossRefPubMed

Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001, 86: 51-56.PubMed

Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001,29(Suppl 7):S90-94. 10.1097/00003246-200107001-00028CrossRefPubMed

Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996, 88: 881-886.PubMed

Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Narey P, Lestavel P: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies [see comments]. Chest 1992, 101: 816-823.CrossRefPubMed

Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000, 95: 1117-1123.PubMed

Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation 109: 2698-2704. 10.1161/01.CIR.0000131660.51520.9A

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed

Levi M, ten Cate H, van der Poll T: Disseminated intravascular coagulation: State of the art. Thromb Haemost 1999, 82: 695-705.PubMed

10.

Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Penzes I, Kubler A, Knaul S, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001, 286: 1869-1878. 10.1001/jama.286.15.1869CrossRef

11.

Blauhut B, Kramar H, Vinazzer H, Bergmann H: Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985, 39: 81-89. 10.1016/0049-3848(85)90123-9CrossRefPubMed

12.

Bernard GR, Ely EW, Wright TJ, Stasek JE, Russell JA, Norris PE, Yau SB, Helterbrand JD: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003CrossRefPubMed

13.

Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86: 1327-1330.PubMed

14.

Dhainaut JF, Yan SB, Joyce DE, Petilla V, Busson BR, Brauelt JT, Saudin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2: 1924-1933. 10.1111/j.1538-7836.2004.00955.xCrossRefPubMed

Titel: Antithrombin in sepsis revisited
verfasst von: Marcel Levi
Publikationsdatum: 01.12.2005
Verlag: BioMed Central
Erschienen in: Critical Care / Ausgabe 6/2005
Elektronische ISSN: 1364-8535
DOI: https://doi.org/10.1186/cc3819

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Antithrombin in sepsis revisited

Abstract

Neu im Fachgebiet AINS

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2005

Prediction of ventilation weaning outcome: children are not little adults

Lactate as a marker of energy failure in critically ill patients: hypothesis

Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study

Early veno-venous haemodiafiltration for sepsis-related multiple organ failure

Bench-to-bedside review: Paediatric viral lower respiratory tract disease necessitating mechanical ventilation – should we use exogenous surfactant?

Central venous catheter-related infection in a prospective and observational study of 2,595 catheters

Neu im Fachgebiet AINS

Akuter Schwindel: Wann lohnt sich eine MRT?

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Update AINS